Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-401 (zedenoleucel) in AML following HSCT
NCT04511130Phase 2Terminated
- Sponsor
- Marker Therapeutics, Inc.
- Start
- Oct 2020
- Primary completion
- Mar 2024
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MT-401 in acute myeloid leukemia (AML), sponsored by Marker Therapeutics, Inc.. Started Oct 2020; status: terminated.
02
Drugs
MT-401
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04511130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511130.